VivoSeq
Other

Hutchinson-Gilford Progeria Syndrome

4

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Hutchinson-Gilford progeria syndrome is an early-stage landscape with 4 programs across 4 companies. The most active players are Sentynl Therapeutics, Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Pfizer. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sentynl Therapeutics, Inc.

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedE

Eiger BioPharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Approved for marketing1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Completed·AAssistance Publique Hopitaux De Marseille·Phase 2·NCT00731016·15 enrolled
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
Approved for marketing·EEiger BioPharmaceuticals·N/A·NCT03895528
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
Active, not recruiting·PPRG Science & Technology Co., Ltd.·Phase 2·NCT06775041·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)